{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:32Z","timestamp":1792417412005,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Innovation Guidance Fund of Hangzhou Medical College","award":["CX2022019"],"award-info":[{"award-number":["CX2022019"]}]},{"name":"Special Fund Project of Zhejiang Provincial Medical Association Clinical Medicine","award":["2024ZYC-B100"],"award-info":[{"award-number":["2024ZYC-B100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-04502-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:14:00Z","timestamp":1784729640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Chunxiu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0001-5643","authenticated-orcid":false,"given":"Huiting","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"4502_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1245\/s10434-020-08653-w","volume":"28","author":"J Lagergren","year":"2021","unstructured":"Lagergren J, Bottai M, Santoni G. Patient age and survival after surgery for esophageal cancer. Ann Surg Oncol. 2021;28(1):159\u201366.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4502_CR2","first-page":"500","volume":"43","author":"YL Qiao","year":"2016","unstructured":"Qiao YL. An important milestone in the epidemiological study of esophageal cancer. Chin J Clin Oncol. 2016;43(12):500\u20131.","journal-title":"Chin J Clin Oncol"},{"issue":"3","key":"4502_CR3","first-page":"228","volume":"42","author":"YS Mao","year":"2020","unstructured":"Mao YS, Gao SG, Wang Q, et al. Epidemiological characteristics and current status of surgical treatment for esophageal cancer by analysis of national registry database. Chin J Oncol. 2020;42(3):228\u201333.","journal-title":"Chin J Oncol"},{"issue":"4","key":"4502_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3892\/ol.2015.3624","volume":"10","author":"J Chen","year":"2015","unstructured":"Chen J, Wu F, Pei HL, et al. Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer. Oncol Lett. 2015;10(4):2197\u2013203.","journal-title":"Oncol Lett"},{"issue":"17","key":"4502_CR5","first-page":"1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u2009\u2013\u200901). Radiation Therapy Oncol Group JAMA. 1999;281(17):1623\u20137.","journal-title":"Radiation Therapy Oncol Group JAMA"},{"issue":"1","key":"4502_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1\/PD-1 mediated tumor immune escape. Mol Cancer. 2019;18(1):10.","journal-title":"Mol Cancer"},{"issue":"5","key":"4502_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cam4.106","volume":"2","author":"DF McDermott","year":"2013","unstructured":"McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662\u201373.","journal-title":"Cancer Med"},{"issue":"10","key":"4502_CR8","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310\u20137.","journal-title":"J Clin Oncol"},{"key":"4502_CR9","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","volume":"8","author":"HR Mirzaei","year":"2017","unstructured":"Mirzaei HR, Rodriguez A, Shepphird J, et al. Chimeric antigen receptors T cell therapy in solid tumor challenges and clinical applications. Front Immunol. 2017;8:1850.","journal-title":"Front Immunol"},{"issue":"1","key":"4502_CR10","first-page":"11","volume":"1","author":"X Jiao","year":"2021","unstructured":"Jiao X, Lu ZH. An annual review of advances in esophageal cancer in 2020. J Multidiscip Cancer Manag (Electr Vers). 2021;1(1):11\u20136.","journal-title":"J Multidiscip Cancer Manag (Electr Vers)"},{"issue":"6","key":"4502_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):648\u201358.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"4502_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"issue":"20","key":"4502_CR13","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"17suppl","key":"4502_CR14","doi-asserted-by":"publisher","first-page":"LBA5","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5","volume":"42","author":"DR Spigel","year":"2024","unstructured":"Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer. J Clin Oncol. 2024;42(17suppl):LBA5.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4502_CR15","first-page":"1593","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(11):1593\u2013600.","journal-title":"JAMA Oncol"},{"issue":"Suppl 7","key":"4502_CR16","first-page":"S667","volume":"33","author":"J Wang","year":"2022","unstructured":"Wang J, et al. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer. Ann Oncol. 2022;33(Suppl 7):S667.","journal-title":"Ann Oncol"},{"issue":"1","key":"4502_CR17","doi-asserted-by":"publisher","first-page":"1971418","DOI":"10.1080\/2162402X.2021.1971418","volume":"10","author":"W Zhang","year":"2021","unstructured":"Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology. 2021;10(1):1971418.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04502-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04502-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04502-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:03:48Z","timestamp":1792415028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04502-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4502"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04502-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7815083\/v1","asserted-by":"object"}]},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"811"}}